estudio soul semaglutide Congreso ACC 2025 – oral y eventos cardiovasculares en diabetes tipo 2 de alto riesgo – SIAC The SOUL Study - by
Description
Random-effects models were employed for the pooled analysis, and heterogeneity was evaluated using the I2 statistic
Curious about microdosing GLP-1s
Eli Lilly (NYSE:LLY) plans to invest over US$3.5b in a new Pennsylvania manufacturing facility focused on next generation injectable weight loss therapies
Get legal help for Ozempic lawsuits from Dolinsky Law Group
Eli Lilly stock rallies as the firms oral weight-loss pill, Foundayo, secures FDA approval
Result: GLP-1s lowered osteoporosis risk (31% reduction)
